

CBER Critical Path Initiative Workshop 07 October 04

Jonathan C. Goldsmith, MD
Immune Deficiency Foundation
40 West Chesapeake Avenue
Towson, Maryland, USA



- Standardized Assays for Therapeutic Antibodies
 - Selection of clinically relevant antibodies
 - Expansion of CFR required tests
 - Consensus development workshop to resolve selections
 - Correlation of Potency with Effectiveness
 - Development of functional assays



- Surrogate Markers to license new agents
 - Antibodies with specificity for encapsulated organisms
 - Analysis of sera banks from recent licensure trials



- Safety Issues
 - Universal integration of biologically relevant established procedures for plasma derivatives
 - pathogen clearance
 - prion removal/inactivation
 - Role for FDA
 - Scientific evaluation of procedures



- Exploration of the role of animal models in facilitating licensure of new products
 - Antibodies that cannot be ethically tested
 - Agents of bioterrorism
 - Emerging Infectious Diseases

